Ligaba Drug Interactions

Since it is predominantly excreted unchanged in the urine, undergoes negligible metabolism in human (<2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro and in vivo studies showed that it is unlikely to be involved in significant pharmacokinetic interactions. Specifically, there is no pharmacokinetic interactions between pregabalin and the following antiepileptic drugs: carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate. Important pharmacokinetic interactions would also not be expected to occur between this drug and commonly used antiepileptic drugs.
Pharmacodynamics: Multiple oral doses were co-administered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and gross motor functioning were seen when co-administered with these drugs. No clinically important effects on respiration were seen.